



THE NOVELTY STUDY

Identifying new dimensions in respiratory disease

NOVELTYstudy.com

Publication alert:

The burden of mild asthma: clinical burden and healthcare resource utilisation in the NOVELTY study

Sarowar Muhammad Golam, Christer Janson, Richard Beasley, J Mark FitzGerald, Tim Harrison, Bradley Chipps, Rod Hughes, Hana Müllerová, José María Olaguibel, Eleni Rapsomaniki, Helen K Reddel, Mohsen Sadatsafavi, for the NOVELTY study investigators


Respiratory Medicine 2022; 200: 106863.

- Patients with **mild asthma** represent a **substantial proportion** of the **population with asthma**, yet there are **limited data** on their true **burden of disease**
- In the 2012/2013 UK National Review of Asthma Deaths, **14 (9%) of 155 patients who died of asthma were receiving treatment for mild asthma prior to death**,* indicating a potential **treatment gap** for patients who are assessed as having **mild asthma**


Objective

Describe the clinical and healthcare resource utilisation burden[†] in patients with physician-assessed mild asthma[‡] from the real-world global NOVELTY population

Out of 2,004 patients with mild asthma:



Out of 625 exacerbations reported in the previous 12 months:



A similar disease burden pattern was observed in a sensitivity analysis of patients with asthma on GINA 2017 treatment steps 1 or 2

- In this global sample representing community practice, a **significant proportion** of patients with **physician-assessed mild asthma** had **considerable clinical burden and healthcare resource utilisation**
- **Quality of care improvements** are required in the **assessment of asthma severity and achieving asthma control**

The NOVELTY study is sponsored by AstraZeneca.

Data for patients from China were excluded from the present analyses due to a change in regulations about data transfer in May 2019.

*Royal College of Physicians. Why asthma still kills: the National Review of Asthma Deaths (NRAD) confidential enquiry report. London: RCP, 2014. <https://www.rcplondon.ac.uk/projects/outputs/why-asthma-still-kills> (Accessed June 28, 2022).

[†]Clinical burden included physician-reported exacerbations and patient-reported outcomes. Healthcare resource utilisation burden included inpatient and outpatient visits.

[‡]Diagnosis and severity were based on physician assessment, with no diagnostic or severity criteria specified.

[§]Symptom control was assessed using the Asthma Control Test.

COPD, chronic obstructive pulmonary disease; GINA, Global Initiative for Asthma; NOVELTY, NOVEL observational longiTudinal studY.

Reference

Golam SM, et al. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study. Respiratory Medicine 2022; 200: 106863.